ArticleRheumatology international2012
Power Doppler ultrasonography is useful for assessing disease activity and predicting joint destruction in rheumatoid arthritis patients receiving tocilizumab--preliminary data.
Article in Rheumatology international, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Elevated baseline power Doppler discriminates an RA subgroup highly responsive to therapy.Rheumatology (Oxford, England) · 2015Trial
- Article
- Optimizing Reliability of Real-Time Sonographic Examination and Scoring of Joint Synovitis in Rheumatoid Arthritis.Cureus · 2022Article
- Doppler ultrasound impacts response to intravenous tocilizumab in rheumatoid arthritis patients.Clinical rheumatology · 2021Article
- Ultrasound detects synovitis in replaced and other surgically operated joints in rheumatoid arthritis patients.BMC rheumatology · 2020Article
- Clinical utility of eco-color-power Doppler ultrasonography and contrast enhanced magnetic resonance imaging for interpretation and quantification of joint synovitis: a review.Acta bio-medica : Atenei Parmensis · 2018Review
- Joint-specific assessment of swelling and power Doppler in obese rheumatoid arthritis patients.BMC musculoskeletal disorders · 2017Article
- Use of ultrasound in treatment decisions for patients with rheumatoid arthritis: an observational study in Italy.Clinical rheumatology · 2016Observational
- Prediction of Large Joint Destruction in Patients With Rheumatoid Arthritis Using 18F-FDG PET/CT and Disease Activity Score.Medicine · 2016Observational
- [18F]fluorodeoxyglucose uptake as a predictor of large joint destruction in patients with rheumatoid arthritis.Rheumatology international · 2016Article
- Application of contrast-enhanced ultrasonography and ultrasonography scores in rheumatoid arthritis.International journal of clinical and experimental medicine · 2015Article
- The Role of Power Doppler Ultrasonography as Disease Activity Marker in Rheumatoid Arthritis.Disease markers · 2015Review
- Application of high frequency color Doppler ultrasound in the monitoring of rheumatoid arthritis treatment.Experimental and therapeutic medicine · 2014Article
- Clinical and ultrasound evaluation of the response to tocilizumab treatment in patients with rheumatoid arthritis: a case series.Rheumatology international · 2014Article
- Musculoskeletal ultrasonography in patients with rheumatoid arthritis.Nature reviews. Rheumatology · 2013Review
- Mechanistic biomarkers for clinical decision making in rheumatic diseases.Nature reviews. Rheumatology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate the responsiveness of power Doppler ultrasonography (PDUS) in comparison with conventional measures of disease activity and structural damage in rheumatoid arthritis (RA) patients receiving tocilizumab (TCZ). Seven RA patients with active arthritis were enrolled in the study and prospectively monitored for 12 months. They were treated with TCZ (8 mg/kg) every 4 weeks as monotherapy or in combination with disease-modifying antirheumatic drugs (DMARDs). Clinical, laboratory, and ultrasound examinations were conducted at baseline, 1, 3, 6, 9, and 12 months. Power Doppler (PD) signals were graded from 0 to 3 in 24 joints, and total PD score was calculated as the sum of scores of individual joints. One-year radiographic progression of the hands was estimated by using Genant-modified Sharp scoring. The averages of the clinical parameters rapidly improved, and all patients achieved good response within 6 months based on standard 28-joint Disease Activity Score (DAS28). Although the average total PD score declined in parallel with clinical improvement, radiography of the hands showed progression of destruction in the joints where PD signals remained, even among clinical responders. ΔSharp score correlated with the time-integrated value (TIV) of total PD scores (Δtotal Sharp score: r = 0.77, P = 0.04; Δerosion: r = 0.78, P = 0.04; Δjoint-space narrowing (JSN): r = 0.75, P = 0.05), but not with TIVs of clinical parameters including DAS28. PDUS can independently evaluate disease activity in RA patients receiving TCZ and is superior to DAS28, especially in predicting joint destruction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.